Neonatal screening for sickle cell disease in France: evaluation of the selective process

@article{Thuret2010NeonatalSF,
  title={Neonatal screening for sickle cell disease in France: evaluation of the selective process},
  author={I. Thuret and J. Sarles and F. Merono and E. Suzineau and J. Collomb and D. Lena-Russo and N. L{\'e}vy and J. Bardakdjian and C. Badens},
  journal={Journal of Clinical Pathology},
  year={2010},
  volume={63},
  pages={548 - 551}
}
Aims The French national programme for neonatal screening of sickle cell disease is applied to newborns ‘at risk’, defined as those born to parents originating from sub-Saharan Africa, the Mediterranean area, the Arabic peninsula, the French overseas islands and the Indian subcontinent. The selection is performed by the nurse in charge of blood sampling by interviewing the mother about the family's geographical origins. The mean rate of testing in France is 25%, ranging from 2% to 50% depending… Expand
A Multi-centre Survey of Acceptability of Newborn Screening for Sickle Cell Disease in Nigeria
TLDR
This study suggests that there is a good acceptability of NBS across Nigeria, and the main barriers to its use are likely to be financial and practical, rather than social or cultural. Expand
[Neonatal screening for sickle cell disease at the Nice University Hospital: the last 8 years].
TLDR
Screening for sickle cell disease appears effective in Nice, and the number of children screened is increasing, thanks to better awareness among medical staff and the importance of screening among maternity healthcare actors seems necessary. Expand
Newborn Screening for Sickle Cell Disease: Jamaican Experience.
TLDR
The methods currently detailed provide an effective and economic model of newborn screening which may be of value elsewhere and is known to reduce its morbidity and mortality. Expand
Fifteen years of newborn sickle cell disease screening in Madrid, Spain: an emerging disease in a European country
TLDR
The Madrid SCD NBS program achieved high rates of sensitivity and specificity and good quality of care assistance, and a multidisciplinary team that includes social workers and a psychologist are needed to ensure the success of early intervention. Expand
Newborn Screening for Sickle Cell Disease in Europe
The history of newborn screening (NBS) for sickle cell disease (SCD) in Europe goes back almost 40 years. However, most European countries have not established it to date. The European screening mapExpand
Screening for sickle cell disease in newborns: a systematic review
TLDR
A Jamaican retrospective study evaluating newborn screening for SCD followed by preventive measures (prevention of infections and education of parents) and data from this single retrospective study suggest a benefit of newborn Screening forSCD (followed by preventive Measures) versus no newborn screeningFor SCD (weak certainty of conclusions). Expand
Newborn screening for sickle cell disease in Europe: recommendations from a Pan‐European Consensus Conference
TLDR
This paper aims to summarise the discussions and present consensus recommendations which can be used to support the development of NBS programmes in European countries where they do not yet exist, and to review existing programmes. Expand
Universal screening for hemoglobinopathies in today's multi-ethnic societies: How and when
TLDR
Adding hemoglobinopathies to the routine rhesus screening using a simple separation of the Hb fractions on dedicated devices will virtually identify all female carriers of all common traits responsible for the severe conditions mainly sickle cell disease and thalassemia major in time for partner analysis, counseling and primary prevention. Expand
Genetic Epidemiology and Preventive Healthcare in Multiethnic Societies: The Hemoglobinopathies
TLDR
Identification of carriers using simple and inexpensive methods should be included in the Rhesus and infectious diseases screening which is offered early in pregnancy in most developed countries to allow identification of couples at risk in time for an informed choice and for prenatal diagnosis if required before the first affected child is born. Expand
Newborn screening for haemoglobinopathies by high performance liquid chromatography (HPLC): diagnostic utility of different approaches in resource-poor settings
TLDR
The β-thal short kit was more versatile than the sickle cell short kit for screening for haemoglobinopathies in newborns in India, and the diagnosis of α thalassaemia was difficult to diagnose. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 14 REFERENCES
The feasibility of using ethnicity as a primary tool for antenatal selective screening for sickle cell disorders: pointers from the research evidence.
TLDR
An examination of the evidence base on the use of ethnicity as a primary screening tool reveals substantial variability in practice and in the quality of data collected, with risk group misclassification as high as 20% against a recommended target of under 5.5%. Expand
Neonatal screening for sickle cell disease: a cost-effectiveness analysis.
TLDR
Screening black infants is very worthwhile, but screening populations in which the hemoglobin S gene is rare is unjustified, and screening low prevalence populations would cost $450 billion per life saved. Expand
Implementation of the French nationwide cystic fibrosis newborn screening program.
OBJECTIVES To describe optimization of a nationwide newborn screening program for cystic fibrosis (CF) that combines an immunoreactive trypsinogen (IRT) assay and DNA mutation analysis in dried bloodExpand
Newborn screening for sickle cell disease: effect on mortality.
TLDR
Ten years of experience in newborn screening for sickle cell disease have been summarized and hemoglobinopathies are the most prevalent congenital disease. Expand
Universal versus targeted screening of infants for sickle cell disease: a cost-effectiveness analysis.
TLDR
Universal screening compared with targeted screening always identifies more infants with disease, prevents more deaths, and is cost-effective given certain delivery rates for targeted screening and proportions of African Americans in the population. Expand
Is universal neonatal hemoglobinopathy screening cost-effective?
  • A. Bergman
  • Medicine
  • Archives of pediatrics & adolescent medicine
  • 1995
The article by Sprinkle et al 1 published in the May issue of theArchivesis an example of how the "science" of economics can be employed to justify most any conclusion. Costs and benefits depend onExpand
Newborn screening for hemoglobinopathies in Colorado. The first 10 years.
TLDR
The results of the experience confirm the value of newborn screening for hemoglobinopathies but suggest that a more sensitive test would improve the program. Expand
Costing model for neonatal screening and diagnosis of haemoglobinopathies
TLDR
IEF and HPLC are very similar in terms of average cost per test, and at 16 traits/1000 and 0.5 SCD/1000 there was no significant identification cost difference between universal and targeted programmes. Expand
Neonatal screening for congenital hypothyroidism based on thyroxine, thyrotropin, and thyroxine-binding globulin measurement: potentials and pitfalls.
TLDR
The Dutch incidence figures for CH belong to the highest worldwide, suggesting that the T(4)-TSH-TBG screening program is an efficient method to detect CH of variable etiology and severity, although a small percentage of children with CH escaped detection via this screening approach. Expand
A cost-effectiveness evaluation of newborn hemoglobinopathy screening from the perspective of state health care systems.
TLDR
Each state should determine the most cost-effective strategy for newborn hemoglobinopathy screening from the perspective of state health care systems based on state-specific values for sickle cell disease prevalence, test costs and racial targeting costs. Expand
...
1
2
...